PRESS RELEASES

<< Back
Feb 23, 2017

Chimerix to Announce Fourth Quarter and Full Year 2016 Financial Results on March 2, 2017

DURHAM, N.C., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company committed to discovering, developing and commercializing medicines that address significant, unmet medical needs, today announced that it will host a live conference call and audio webcast on Thursday, March 2, 2017 at 8:30 a.m. ET to report financial results for the fourth quarter and full year ended December 31, 2016, and to provide a business overview.

To access the live conference call, please dial (877) 354-4056 (domestic) or (678) 809-1043 (international) at least five minutes prior to the start time, and refer to conference ID 77533539. A live audio webcast of the call will also be available on the Investors' section of the Company's website, www.chimerix.com. An archived webcast and accompanying slides will be available on the Chimerix website approximately two hours after the event.

About Chimerix
Chimerix is a biopharmaceutical company committed to discovering, developing and commercializing medicines that address significant, unmet medical needs. Chimerix's proprietary lipid conjugate technology has produced brincidofovir (BCV); CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage clinical candidates. Chimerix recently announced a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com .

CONTACT:



Investor Relations:



ir@chimerix.com

or

Will O'Connor

Stern Investor Relations

Will@sternir.com

212-362-1200



Media:



Becky Vonsiatsky

W2O Groupbvonsiatsky@w2ogroup.com

413-478-2003

Primary Logo

Source: Chimerix, Inc.

News Provided by Acquire Media